Article

Herbert Irving Comprehensive Cancer Center Joins OncLive's Strategic Alliance Partnership

Author(s):

OncLive is pleased to announce that the Herbert Irving Comprehensive Cancer Center has joined its Strategic Alliance Partnership program.

FOR IMMEDIATE RELEASE

OncLive Gives Partners a Forum for Their Research, Events & Initiatives

PLAINSBORO, N.J. — May 7, 2013 – OncLive® is pleased to announce that the Herbert Irving Comprehensive Cancer Center has joined its Strategic Alliance Partnership program.

This program enables the Herbert Irving Comprehensive Cancer Center to promote its institution and faculty as leaders in oncology to a national audience of oncology professionals through OncologyLive, Oncology & Biotech News, Oncology Nursing News, and www.OncLive.com.

OncLive offers a suite of leading oncology publications and websites, and through its reach provides oncology professionals with the latest data and cutting-edge research. Through the partnership, both parties will benefit from shared knowledge and increased visibility in the oncology community.

The Herbert Irving Comprehensive Cancer Center is Columbia University’s organizational structure for the conduct of cancer research and patient care. It is one of only 41 National Cancer Institute-designated comprehensive cancer centers in the country.

“We are thrilled to have the Herbert Irving Comprehensive Cancer Center on board as a strategic partner,” said Jack Lepping, president of the oncology division of Intellisphere, the publisher of OncLive. “The Herbert Irving Comprehensive Cancer Center is a national leader in research, and we can’t wait to share more of its faculty’s important work with our readers.”

This year, 15 cancer centers and nursing schools have joined OncLive’s Strategic Alliance Partnership program.

To learn more the Strategic Alliance program, visit www.onclive.com/sap-partner. About OncLive®

OncLive is the official website for Intellisphere’s Oncology Specialty Group, which publishes Oncology & Biotech News, OncologyLive, Oncology Nursing News, and Contemporary Oncology. The mission of OncLive and its family of publications is to provide oncology professionals with the resources and information they need to provide the best care for their patients. The Oncology Specialty Group is a division of Intellisphere, LLC, a leading provider of health care publishing, research and education. To learn more, please visit www.OncLive.com.

Media Contact:

Mike Gross

For OncLive

856-628-6169

mike@hornercom.com

Related Videos
Cedric Pobel, MD
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.